Related Experiment Video
Updated: May 27, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Renal denervation a new treatment option in resistant arterial hypertension]
F Himmel1, F Bode, H Schunkert
1Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein, Campus Lübeck. frank.himmel@uk-sh.de
Abstract:
Resistant hypertension is defined as blood pressure that remains above therapeutic goal despite the use of 3 antihypertensive drugs including a diuretic. After exclusion of secondary causes and medical in compliance, the estimated prevalence of resistant arterial hypertension ranges from 4% to 19% in hypertensive patients. Treatment requires a multimodal therapeutic approach. Hyperactivation of the sympathetic nervous system plays a key role in the genesis of hypertension. Targeting renal sympathetic nerves, percutaneous catheter-based renal denervation is a new therapeutic option for the treatment of resistant arterial hypertension in selected drug resistant patients.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure V: Medical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antihypertensive Drugs: Vasodilators
